HSAP9 and CUL2 in prostate tissue and adenocarcinoma
Published: 22 February 2021| Version 1 | DOI: 10.17632/6732npdk5y.1
In the present study, we evaluated whether HSPA9 and CUL2 immunoexpression is greater in carcinoma than in non-neoplastic prostate tissue and whether Gleason patterns 3 and 4 increased the risk of Gleason score 6 and 7 (3+4) adenocarcinoma, biochemical persistence (BP), biochemical recurrence (BR), biochemical failure after adjuvant therapy (FB-ADJ), biochemical failure after prostatectomy (FB-PRS), biochemical failure after salvage radiotherapy (FB-RT), biochemical failure after salvage hormone and radiotherapy (FB-HTRT), biochemical failure after salvage therapy (BF-SAL) and systemic disease (SD).
Steps to reproduce
These data are in SPSS v 26 Format
Universidade Federal do Ceara, Hospital Haroldo Juacaba
Oncology, Urology, Anatomical Pathology